Dr. Golshan serves at the Medical Director of International Oncology Programs at the Dana Farber/Brigham and Womenâ€™s Cancer Center and is the incumbent Dr. Abdul Mohsen and Sultana Al-Tuwaijri Distinguished Chair in Surgical Oncology at the Brigham and Womenâ€™s Hospital. Dr. Golshan is also the Director of Breast Surgical Services at the Dana Farber/Brigham and Women's Cancer Center and an Associate Professor of Surgery at Harvard Medical School. Dr. Golshan helps coordinate international oncology relations at DFBWCC with institutions around the world. Dr. Golshan leads one of the worldâ€™s largest breast surgery programs of 11 full-time breast surgeons operating on nearly 2800 women a year. He organizes the clinical and research efforts of the breast surgeons at the Brigham and Womenâ€™s Hospital and Dana Farber Cancer Institute.
Dr. Golshan's research interest is focused primarily on neoadjuvant therapies for breast cancer and the use of novel imaging and operative technologies targeting breast carcinoma. The focus of the preoperative therapy trials is to target treatment for women with cancer and develop genotypic profiles that will in the future lead to individualized tailored therapies for women with breast cancer. The role of intraoperative and preoperative imaging is also an area of research. In the United States, nearly 40% of women who undergo lumpectomy will need a second operation to achieve clear margins. We are currently trying to determine if more accurate tumor assessment with breast MRI prior to surgery will lead to a decrease in the number of operative procedures required to achieve clear margins. We are also working on the use of intraoperative imaging assessment with breast MRI in the Advanced Multimodality Image Guided Operative Suite (AMIGO) to determine if we can find residual tumor while the patient is under anesthesia and improve operative outcomes.